Welcome to our dedicated page for DRUGS MADE IN AMER ACQUISITION SEC filings (Ticker: DMAAU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drugs Made In America Acquisition Corp. (DMAAU) is a blank check company whose securities are registered in connection with its initial public offering on the Nasdaq Global Market. Although no specific SEC filings are listed here in this dataset, the company’s public statements reference a registration statement on Form S‑1 that was declared effective by the U.S. Securities and Exchange Commission in connection with its IPO, along with a post‑effective amendment.
As a SPAC and shell company in the financial services sector, DMAAU’s SEC filings are expected to describe its structure as a Cayman Islands exempted company, the terms of its units, ordinary shares, and rights, and the general framework for its planned business combination activities. These documents typically outline the company’s intention to pursue a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses.
The company has stated that it intends to focus its search for a target in the pharmaceutical industry, with an emphasis on businesses that may help mitigate risks in the U.S. medical supply chain by supporting strategic on‑shoring of advanced domestic manufacturing technologies for critical drugs. Over time, investors can expect that key SEC reports, such as annual and quarterly reports and any merger‑related filings, would provide more detail on its acquisition progress and any proposed business combination.
On Stock Titan’s SEC filings page, users can access DMAAU’s regulatory documents as they become available through EDGAR, along with AI‑generated summaries that explain the structure and implications of each filing. This includes registration statements and, if and when they are filed, ongoing reports and any transaction‑related disclosures that describe the company’s efforts to complete an initial business combination.
Drugs Made in America Acquisition Corp. reported that shareholders approved an Extension Proposal at an Extraordinary General Meeting held on April 27, 2026, allowing the SPAC more time to complete a business combination. The proposal passed by special resolution with 18,906,281 votes for and 4,892,646 against.
As of the April 7, 2026 record date, 33,517,143 ordinary shares were issued and outstanding, and 23,798,927 shares were voted, representing about 70.58% of eligible shares. In connection with the vote, holders of 9,440,230 ordinary shares elected to redeem for cash from the trust.
The company will remove $99,336,016.67, or about $10.52 per share, from its trust account to pay redeeming holders. After these redemptions, 24,276,913 ordinary shares will remain outstanding, including 13,559,770 sold in the initial public offering. The Board approved an initial one‑month extension of the SPAC’s term to May 29, 2026.
Drugs Made in America Acquisition Corp. reported that shareholders approved an Extension Proposal at an Extraordinary General Meeting held on April 27, 2026, allowing the SPAC more time to complete a business combination. The proposal passed by special resolution with 18,906,281 votes for and 4,892,646 against.
As of the April 7, 2026 record date, 33,517,143 ordinary shares were issued and outstanding, and 23,798,927 shares were voted, representing about 70.58% of eligible shares. In connection with the vote, holders of 9,440,230 ordinary shares elected to redeem for cash from the trust.
The company will remove $99,336,016.67, or about $10.52 per share, from its trust account to pay redeeming holders. After these redemptions, 24,276,913 ordinary shares will remain outstanding, including 13,559,770 sold in the initial public offering. The Board approved an initial one‑month extension of the SPAC’s term to May 29, 2026.
Drugs Made In America Acquisition Corp. reported new executive compensation arrangements. On April 22, 2026, it signed an updated Statement of Work with Titan Advisory Services, which supplies Chief Financial Officer services from Saleem Elmasri under a consulting structure.
The prior consulting terms included $3,500 in monthly compensation and a grant or transfer of 100,000 ordinary shares to Mr. Elmasri upon engagement. On the same date, the company also entered into a CEO Compensation Agreement with Aleutian Equity Holdings LLC, the designated compensation vehicle for Chief Executive Officer Roger E. Bendelac, including customary indemnification and limitation-of-liability provisions.
Drugs Made In America Acquisition Corp. reported new executive compensation arrangements. On April 22, 2026, it signed an updated Statement of Work with Titan Advisory Services, which supplies Chief Financial Officer services from Saleem Elmasri under a consulting structure.
The prior consulting terms included $3,500 in monthly compensation and a grant or transfer of 100,000 ordinary shares to Mr. Elmasri upon engagement. On the same date, the company also entered into a CEO Compensation Agreement with Aleutian Equity Holdings LLC, the designated compensation vehicle for Chief Executive Officer Roger E. Bendelac, including customary indemnification and limitation-of-liability provisions.
Drugs Made In America Acquisition Corp. filed Amendment No. 1 to its definitive proxy statement to update voting thresholds and share counts tied to an Extraordinary General Meeting. The amendment states 33,517,143 Ordinary Shares outstanding as of the Record Date and elsewhere lists 33,717,143 Ordinary Shares as of the Record Date. It specifies that, assuming all Ordinary Shares are present, the Company will need 11,827,619 and alternatively 11,760,953 Public Shares to approve the Extension Proposal, and 6,241,429 and alternatively 6,141,429 Public Shares to approve the Adjournment Proposal. The Amendment replaces Article 48.7 and is dated April 16, 2026.
Drugs Made In America Acquisition Corp. filed Amendment No. 1 to its definitive proxy statement to update voting thresholds and share counts tied to an Extraordinary General Meeting. The amendment states 33,517,143 Ordinary Shares outstanding as of the Record Date and elsewhere lists 33,717,143 Ordinary Shares as of the Record Date. It specifies that, assuming all Ordinary Shares are present, the Company will need 11,827,619 and alternatively 11,760,953 Public Shares to approve the Extension Proposal, and 6,241,429 and alternatively 6,141,429 Public Shares to approve the Adjournment Proposal. The Amendment replaces Article 48.7 and is dated April 16, 2026.
Drugs Made In America Acquisition Corp., a Cayman Islands-based blank check company, filed its annual report detailing progress and risks as it searches for a merger target. The SPAC raised $231.15 million in trust from its IPO and private placements and reported 2025 net income of $5.94 million, driven by $8.76 million of interest on trust investments.
The company remains a shell with no operations and faces a going concern uncertainty due to limited cash outside the trust and a deadline to complete a business combination. It is seeking to extend its combination period up to April 29, 2027 through shareholder approval and sponsor-funded monthly trust contributions.
Governance shifted significantly after the prior CEO resigned in early 2026 following issues at an affiliated SPAC sponsor, and a new CEO and CFO were appointed. DMAA secured a $500,000 convertible note commitment, including a $100,000 interim loan, and signed a non-binding LOI with Power Analytics Global Corp. for a potential $1.0 billion de‑SPAC transaction, which remains subject to negotiation and diligence. Management also disclosed material weaknesses in internal controls and plans remediation.
Drugs Made In America Acquisition Corp., a Cayman Islands-based blank check company, filed its annual report detailing progress and risks as it searches for a merger target. The SPAC raised $231.15 million in trust from its IPO and private placements and reported 2025 net income of $5.94 million, driven by $8.76 million of interest on trust investments.
The company remains a shell with no operations and faces a going concern uncertainty due to limited cash outside the trust and a deadline to complete a business combination. It is seeking to extend its combination period up to April 29, 2027 through shareholder approval and sponsor-funded monthly trust contributions.
Governance shifted significantly after the prior CEO resigned in early 2026 following issues at an affiliated SPAC sponsor, and a new CEO and CFO were appointed. DMAA secured a $500,000 convertible note commitment, including a $100,000 interim loan, and signed a non-binding LOI with Power Analytics Global Corp. for a potential $1.0 billion de‑SPAC transaction, which remains subject to negotiation and diligence. Management also disclosed material weaknesses in internal controls and plans remediation.
Drugs Made in America Acquisition Corp. is asking shareholders to approve changes that would give it up to 12 extra months, from April 29, 2026 to April 29, 2027, to complete a business combination.
Each one-month extension would require the sponsor to loan the lesser of $300,000 or $0.04 per non‑redeemed public share into the trust account. Public shareholders can redeem shares for about $10.52 per share, based on roughly $242 million held in the trust as of the record date, regardless of how they vote. If the extension is not approved and no deal closes by the current deadline, the SPAC will redeem all public shares and wind up.
Drugs Made in America Acquisition Corp. is asking shareholders to approve changes that would give it up to 12 extra months, from April 29, 2026 to April 29, 2027, to complete a business combination.
Each one-month extension would require the sponsor to loan the lesser of $300,000 or $0.04 per non‑redeemed public share into the trust account. Public shareholders can redeem shares for about $10.52 per share, based on roughly $242 million held in the trust as of the record date, regardless of how they vote. If the extension is not approved and no deal closes by the current deadline, the SPAC will redeem all public shares and wind up.
Drugs Made In America Acquisition Corp. reported leadership changes following issues at an affiliated SPAC’s working capital account. The sponsor of Drugs Made In America Acquisition II Corp. withdrew an aggregate $1,100,000 from the affiliate’s working capital account, including $325,000 to repay a working capital note and $208,000 for other offering costs and expenses. The affiliate’s financial statements also showed a $566,269 overpayment to the sponsor, and the sponsor later withdrew no less than $200,000 more to pay expenses unrelated to the affiliate. After the affiliate’s board directed the sponsor to return the full overpayment amount and learned on February 12, 2026 that it could not be repaid, the boards of the affiliate and the company requested the resignation of Lynn Stockwell as Chief Executive Officer, Executive Chair, and director. The board received her resignation effective February 28, 2026 and removed her from all roles. On the same date, Roger Bendelac was appointed Chief Executive Officer of the company; his compensation will be determined later.
Drugs Made In America Acquisition Corp. reported leadership changes following issues at an affiliated SPAC’s working capital account. The sponsor of Drugs Made In America Acquisition II Corp. withdrew an aggregate $1,100,000 from the affiliate’s working capital account, including $325,000 to repay a working capital note and $208,000 for other offering costs and expenses. The affiliate’s financial statements also showed a $566,269 overpayment to the sponsor, and the sponsor later withdrew no less than $200,000 more to pay expenses unrelated to the affiliate. After the affiliate’s board directed the sponsor to return the full overpayment amount and learned on February 12, 2026 that it could not be repaid, the boards of the affiliate and the company requested the resignation of Lynn Stockwell as Chief Executive Officer, Executive Chair, and director. The board received her resignation effective February 28, 2026 and removed her from all roles. On the same date, Roger Bendelac was appointed Chief Executive Officer of the company; his compensation will be determined later.
Karpus Management reported beneficial ownership of 2,744,109 common shares of Drugs Made In America Acquisition Corp., equal to 8.19% of the class. The shares are held directly in accounts managed by Karpus, which states it has sole voting and sole dispositive power over the shares. Karpus is a New York-formed registered investment adviser that notes it is controlled by City of London Investment Group plc but maintains informational barriers so that voting and investment decisions are made independently by Karpus. The filing indicates the position is held in the ordinary course of business and not for the purpose of changing control of the issuer.